[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Jimbo H, Kamata S, Miura K, Asamoto S, Tada S, Endo T, Masubuchi T, Nakamura N, Fushimi C: Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases. Neurol Med Chir (Tokyo); 2010 Jan;50(1):20-6; discussion 26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases.
  • Cancers of the paranasal sinuses and nasal cavity are the most common malignant tumors of the anterior and anterolateral skull base.
  • The treatment of these tumors affecting the skull base is complex due to the significant anatomical features.
  • Using a combination of adjuvant radiation and chemotherapy, we have achieved a 2-year disease-free survival rate of 90% in these cases.
  • We believe that the optimal management of such malignant tumors involves a multimodal and multidisciplinary team approach.
  • Here we present our recent institutional experience and treatment policy employed during the past 3 years.
  • [MeSH-major] Neurosurgical Procedures / methods. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base / pathology. Skull Base / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Cranial Fossa, Middle / anatomy & histology. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Drug Therapy / methods. Drug Therapy / statistics & numerical data. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Orbit / anatomy & histology. Orbit / pathology. Orbit / surgery. Osteotomy / contraindications. Osteotomy / methods. Paranasal Sinuses / anatomy & histology. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Patient Care Team. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / statistics & numerical data. Reconstructive Surgical Procedures / methods. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098020.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Lavelle C, Birek C, Scott DA: Are nicotine replacement strategies to facilitate smoking cessation safe? J Can Dent Assoc; 2003 Oct;69(9):592-7
Hazardous Substances Data Bank. NICOTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include chronic obstructive pulmonary disease and oral, lung and other cancers, although the morbidity and mortality rates for cerebrovascular disease (e.g., ischemic strokes) and cardiovascular disease (e.g., ischemic myocardial infarction) tend to be greater.
  • Various alternative nicotine sources (e.g., transdermal nicotine patches, nicotine gum, nicotine nasal sprays) have been incorporated into smoking cessation programs.
  • The pathogenic potential of nicotine, regardless of source, and the contraindications to the use of nicotine replacement therapies are discussed.
  • However, the systemic nicotine load in individuals undergoing replacement therapy is generally lower than during active smoking.
  • [MeSH-major] Nicotine / administration & dosage. Nicotinic Agonists / administration & dosage. Smoking Cessation / methods. Tobacco Use Disorder / drug therapy
  • [MeSH-minor] Animals. Canada. Drug Interactions. Humans. Risk Factors. Safety

  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14653935.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Nicotinic Agonists; 6M3C89ZY6R / Nicotine
  • [Number-of-references] 59
  •  go-up   go-down


3. Zagolski O, Dwivedi RC, Subramanian S, Kazi R: Non-Hodgkin's lymphoma of the sino-nasal tract in children. J Cancer Res Ther; 2010 Jan-Mar;6(1):5-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the sino-nasal tract in children.
  • Childhood head and neck cancers are relatively uncommon.
  • Of all head and neck cancers occurring in children, non-Hodgkin's lymphoma (NHL) is the most common, others being rhabdomyosarcoma and nasopharyngeal carcinoma.
  • These can be of several different types depending on the predominant cell type and histologic appearance, the most common histological variant being diffuse large B-cell lymphoma.
  • In an attempt to simplify the classification and to develop a universally acceptable classification and staging, they have been classified and staged numerous times over the last three decades, adding more confusion to the topic.
  • Clinical presentations vary according to the histological type.
  • The low grade lymphomas present with a nasal cavity or para-nasal sinus mass associated with obstructive symptoms and/or lymphadenopathy, while high grade lymphomas present with aggressive signs and symptoms including non-healing ulcer, epistaxis, septal perforation and bony destruction.
  • The primary treatment consists of chemotherapy and / or radiation therapy, which is able to achieve remission in two-third of the patients, however, prognosis remains poor with cumulative five-year survival rates at about 30% for all the types of sino-nasal NHLs.
  • Newer targeted therapy (monoclonal antibodies) and combination therapies (including stem cells) are currently being tested in order to improve survival rates in these patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Nose Neoplasms / pathology. Paranasal Sinus Diseases / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Staging. Prognosis. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479539.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


Advertisement
4. Jang NY, Wu HG, Park CI, Heo DS, Kim DW, Lee SH, Rhee CS: Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. Jpn J Clin Oncol; 2010 Jun;40(6):542-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity.
  • OBJECTIVE: To evaluate the efficacy and toxicity of definitive radiotherapy with or without chemotherapy for T3-4 squamous cell carcinoma of maxillary sinus and nasal cavity.
  • METHODS: Forty-two patients with T3-4N0 squamous cell carcinoma of maxillary sinus (n = 30) and nasal cavity (n = 12) received definitive radiotherapy.
  • Chemotherapy was used in 34 patients and elective neck irradiation was not used.
  • RESULTS: The 5-year overall survival/local control rates were 34%/29% for maxillary sinus cancer and 50%/52% for nasal cavity cancer.
  • For maxillary sinus cancers, a performance status of Eastern Cooperative Oncology Group >or=2 (P = 0.012), biologically equivalent dose <68 Gy (P = 0.011) and no use of chemotherapy (P = 0.037) were significant worse predictors for overall survival on log-rank analysis.
  • Biologically equivalent dose <68 Gy was independently associated with poor local control (hazard ratio, 3.32; 95% confidence interval, 1.38-7.97; P = 0.007) and overall survival (hazard ratio, 2.94; 95% confidence interval, 1.23-7.01; P = 0.015).
  • Regional recurrence occurred in only 1 of 30 patients with maxillary sinus cancer and 4 of 12 patients with nasal cavity.
  • CONCLUSIONS: The treatment outcome was poor and local control was a major problem.
  • High radiation dose, effective chemotherapy and elective neck irradiation for advanced nasal cavity cancers may improve disease control.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / radiotherapy. Nasal Cavity. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Palliative Care. Prognosis. Radiation Injuries. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185459.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


5. Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, Onimaru R, Nishioka T, Shirato H, Fukuda S: Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer; 2009 Oct 15;115(20):4705-14
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience.
  • BACKGROUND: The current study aimed to evaluate the efficacy of superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses.
  • No patient died as a result of treatment toxicity or had a cerebrovascular accident.
  • CONCLUSIONS: Although a single institution experience, the results of the current study suggest that RADPLAT can cure the majority of patients with advanced cancer of the nasal cavity and paranasal sinuses, as well as preserve organs.
  • [MeSH-major] Cisplatin / administration & dosage. Nasal Cavity. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Female. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19634162.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiosulfates; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Preś K, Pośpiech L, Krecicki T, Nadolska B, Kubacka M, Zatoński T, Jabłonka A, Piechnik-Resler D, Jankowska-Konsur A: [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001]. Wiad Lek; 2006;59(11-12):797-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001].
  • Malignant neoplasms of the nose and paranasal sinuses occur rarely but due to late diagnosis and poor treatment effects still remain a serious problem.
  • The aim of the study was the analysis of all nose and paranasal sinus neoplasms treated at Lower Silesia in the years 1992-2001.
  • MATERIAL AND METHODS: In the years 1992-2001 in Lower Silesia region there were 182 patients treated for malignant nose and paranasal sinus tumors.
  • Principal management was combined therapy--surgery with radiotherapy in 84% of the cases.
  • Radiotherapy alone was performed in 8.8% and chemotherapy as palliative treatment in 7.1%.
  • CONCLUSIONS: Unsatisfactory results of treatment are an effect of a high advanced stage of the tumor while diagnosed.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Nose Neoplasms / epidemiology. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging / classification. Nose. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427494.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


7. Taylor JF, Robinson A, Johnson N, Marroquin-Cardona A, Brattin B, Taylor R, Phillips TD: In vitro evaluation of ferrihydrite as an enterosorbent for arsenic from contaminated drinking water. Environ Sci Technol; 2009 Jul 15;43(14):5501-6
Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure has been linked to cancers of the bladder, lungs, skin, kidneys, nasal passages, liver, and the prostate.
  • Ferrihydrite (0.25% w/w) protected adult Hydra at levels up to 200 times the minimal effective concentration (MEC) for As(III) and up to 2.5 times the MEC for As(V).

  • MedlinePlus Health Information. consumer health - Arsenic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 Jan;25(1):76-87 [17852392.001]
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 May;25(5):622-34 [18478481.001]
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2009 May;26(5):733-43 [19680945.001]
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 Feb;25(2):134-45 [18286403.001]
  • [Cites] Toxicol Sci. 1999 Dec;52(2 Suppl):118-26 [10630600.001]
  • [Cites] Bull World Health Organ. 2000;78(9):1093-103 [11019458.001]
  • [Cites] Chemosphere. 2000 Nov;41(10):1543-8 [11057679.001]
  • [Cites] J Am Diet Assoc. 2001 Mar;101(3):294-301 [11269606.001]
  • [Cites] Adv Exp Med Biol. 2002;504:157-71 [11922083.001]
  • [Cites] Arch Environ Contam Toxicol. 2002 Jul;43(1):56-63 [12045875.001]
  • [Cites] Environ Sci Technol. 2002 Nov 1;36(21):4562-9 [12433165.001]
  • [Cites] J Colloid Interface Sci. 2002 Nov 1;255(1):52-8 [12702367.001]
  • [Cites] Ecotoxicol Environ Saf. 2003 Sep;56(1):164-73 [12915149.001]
  • [Cites] Chem Res Toxicol. 2003 Aug;16(8):953-7 [12924922.001]
  • [Cites] Toxicol Appl Pharmacol. 1991 Apr;108(2):253-66 [2017755.001]
  • [Cites] Nat Toxins. 1995;3(4):204-13; discussion 221 [7582618.001]
  • [Cites] Semin Hematol. 1998 Jan;35(1):55-71 [9460809.001]
  • [Cites] J Toxicol Clin Toxicol. 1998;36(7):683-90 [9865236.001]
  • [Cites] J Toxicol Environ Health A. 2005 Mar 12;68(5):353-68 [15799627.001]
  • [Cites] Environ Sci Technol. 2005 Sep 15;39(18):7102-10 [16201635.001]
  • [Cites] Environ Sci Technol. 2006 Feb 15;40(4):1364-70 [16572798.001]
  • [Cites] Environ Res. 2006 May;101(1):1-10 [16171795.001]
  • [Cites] J Environ Sci Health A Tox Hazard Subst Environ Eng. 2006;41(10):2399-428 [17018421.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):281-8 [17005634.001]
  • (PMID = 19708388.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES004917-199001; United States / NIEHS NIH HHS / ES / P42 ES004917; United States / NIEHS NIH HHS / ES / P42 ES004917-199001; United States / NIEHS NIH HHS / ES / P42-ES04917
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Gastrointestinal Agents; 0 / Water Pollutants, Chemical; 39473-89-7 / ferrihydrite; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ NIHMS125421; NLM/ PMC2735052
  •  go-up   go-down


8. Nwaorgu OG, Onakoya PA: Inverted papilloma of the nose and paranasal sinuses: a fifteen-year review. Afr J Med Med Sci; 2002 Sep;31(3):191-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverted papilloma of the nose and paranasal sinuses: a fifteen-year review.
  • Inverted papilloma is a relatively rare epithelial neoplasm of the nose and paranasal sinuses accounting for 0.5-4% of all primary tumours of the nose.
  • This is a retrospective study of fifteen patients with histologically confirmed I.P. of the nose and paranasal sinuses seen from 1986 to 2000 at the Department of Otorhinolaryngology, University College Hospital, Ibadan.
  • Nine patients had conservative surgery (intranasal clearance/antrostomy and external fronto-ethmoidectomy) while the remaining six patients had radical surgery (lateral rhinotomy/medial maxillectomy) at various times.
  • The two patients with SCC had adjunct radiotherapy/chemotherapy in addition.
  • We therefore advocate radical surgery in our environment as the treatment of choice for effective limitation of recurrence.
  • [MeSH-major] Nose Neoplasms / epidemiology. Nose Neoplasms / pathology. Papilloma, Inverted / epidemiology. Papilloma, Inverted / pathology. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Antineoplastic Agents / therapeutic use. Biopsy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Chemotherapy, Adjuvant. Female. Hospitals, University. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / pathology. Nigeria / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12751555.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Bradley PJ, Jones NS, Robertson I: Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg; 2003 Apr;11(2):112-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of esthesioneuroblastoma.
  • Esthesioneuroblastoma is an uncommon malignant neoplasm of the nasal vault that in the past was considered benign or low-grade malignant.
  • Large tumors should be considered for preoperative chemotherapy and postoperative radiotherapy.
  • Local tumor recurrence is not uncommon and is generally related to the attention to local anatomic dissection.
  • Distant metastases may present at any time during the course of the disease, generally within 36 months, and may respond to local radiotherapy or systemic chemotherapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Esthesioneuroblastoma, Olfactory / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures / methods. Prognosis. Radiotherapy / methods. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14515089.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


10. Sato H, Murai K, Kanda T, Mimura R, Hiratsuka Y: Association of chromium exposure with multiple primary cancers in the nasal cavity. Auris Nasus Larynx; 2003 Feb;30(1):93-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of chromium exposure with multiple primary cancers in the nasal cavity.
  • A 56-year-old man who had worked at a chromate factory for 13 years developed squamous cell carcinoma of the left nasal cavity 11 years after retirement.
  • He received intra-arterial chemotherapy, followed by surgery.
  • Two years later, an adenocarcinoma was identified in the same nasal cavity just above the previous surgical region.
  • Microsatellite markers were examined in the second tumor specimen as a possible factor for carcinogenesis; however, replication errors were not observed in any of four loci (D2S123, D3S1067, TP53, D18S474) tested.
  • The present case seems to have resulted from long-term exposure to chromium and, to our knowledge, is the first reported case with multiple primary cancers in the nasal cavity associated with chromium exposure.
  • [MeSH-major] Adrenal Gland Neoplasms / chemically induced. Carcinoma, Squamous Cell / chemically induced. Chromium / adverse effects. Nasal Cavity / pathology. Neoplasms, Multiple Primary / chemically induced. Nose Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12589859.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0R0008Q3JB / Chromium
  •  go-up   go-down


11. Kim CH, Song KS, Kim KS, Kim JY, Lee BJ, Lee JG, Yoon JH: Sulindac sulfide-induced apoptosis in sinonasal cancer cells. Acta Otolaryngol; 2005 Feb;125(2):201-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulindac sulfide-induced apoptosis in sinonasal cancer cells.
  • CONCLUSIONS: These results demonstrate that sulindac sulfide can induce cell death in maxillary cancer cells, and that sulindac sulfide-induced apoptosis is related to the extracellular signal-regulated kinase/p38 MAPK-caspase 3 signaling pathway.
  • OBJECTIVE: Head and neck cancer is the sixth commonest cancer in the human body.
  • Squamous cell carcinoma accounts for most sinonasal cancers.
  • However, little is known regarding the biochemical mechanism(s) of cell death in sinonasal cancers.
  • Recently, human epidemiological and clinical intervention studies have indicated that sulindac, a non-steroidal anti-inflammatory drug, exhibits chemopreventive activity in colorectal cancer.
  • In this study, we aimed to investigate whether sulindac sulfide can induce apoptosis in sinonasal cancer cells and what type of molecular mechanisms induces the death of sinonasal cancer cells.
  • MATERIAL AND METHODS: Sinonasal cancer cells (Asan Medical Center Head and Neck Cancer 5) were treated with various concentrations of sulindac sulfide.
  • RESULTS: Human nasal cavity cancer cells treated with sulindac sulfide underwent cell death, and the induction of apoptosis occurred in a dose-dependent manner.
  • Moreover, sulindac sulfide-induced apoptosis was abolished by treatment with the caspase inhibitor Z-VAD-fmk and the mitogen-activated protein kinase (MAPK) inhibitors PD98059 and SB203580.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Apoptosis / drug effects. Carcinoma, Squamous Cell / drug therapy. Paranasal Sinus Neoplasms / drug therapy. Sulindac / analogs & derivatives. Sulindac / pharmacology. Sulindac / therapeutic use
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / administration & dosage. Amino Acid Chloromethyl Ketones / pharmacology. Caspase Inhibitors. Flavonoids / administration & dosage. Flavonoids / pharmacology. Fluorescence. Humans. Imidazoles / administration & dosage. Imidazoles / pharmacology. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Pyridines / administration & dosage. Pyridines / pharmacology. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880954.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Amino Acid Chloromethyl Ketones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Caspase Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Pyridines; 0 / SB 203580; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 184SNS8VUH / Sulindac; 6UVA8S2DEY / sulindac sulfide; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


12. Hu WH, Xie FY, Fang SH, Jiao JJ, Yan C, Peng WJ, Fu XY, Zhang F: [Cancer of the nasal cavity]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):117-21
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the nasal cavity].
  • OBJECTIVE: To analyze the factors affecting prognosis of patients with nasal carcinoma.
  • The 5-year survival rate was 55.8% in squamous-cell carcinoma, 44.0% in adenocarcinoma, 59.7% in undifferentiated carcinoma, 76.3% in adenoid cystic carcinoma, 71.4% in mucoepidermoid carcinoma, 25.0% in rhabdomyosarcoma, 26.7% in malignant melanoma, 50.0% in neuroblastoma (P > 0.05).
  • The 5-year survival rate was 73.8% in patients whose cancer completely disappeared after treatment.
  • It was 41.6% in patients whose cancer incompletely disappeared, and 34.3% in patients whose cancer remained refractory (P < 0.01).
  • That with chemotherapy only was 25.0% whereas that of patients treated with combination treatment was 61.8% (P > 0.05).
  • CONCLUSION: Clinical stage, immediate therapeutic response and involvement of sphenoidal or maxillary sinus; but not the pathologic type, the presence of cervical metastasis nor the method of treatment, are the factors affecting the prognosis of patients with nasal carcinoma.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / mortality. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946555.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


13. Haddad R, Cohen M, Kaplan O, Greenberg R, Kashtan H: [Photodynamic therapy of nasal basal cell carcinoma]. Harefuah; 2001 Jan;140(1):25-7, 86
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photodynamic therapy of nasal basal cell carcinoma].
  • Photodynamic therapy (PDT) is a noninvasive modality used topically for several skin cancers.
  • We evaluated the effects of PDT on basal cell carcinoma (BCC) of the nose, using aminolevulinic acid (ALA) as a photosensitizer and a non-laser light source (Versa-Light).
  • A paste of 20% ALA was applied topically to biopsy-proven BCC of the nose.
  • Patients who did not respond after 2 treatments were referred for surgery.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Nose Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242893.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


14. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the nasal vestibule, nasal cavity and paranasal sinuses.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


15. Garandawa HI, Ahmad BM, Nggada HA: Nasopharyngeal cancer in North--Eastern Nigeria: clinical trends. Niger J Clin Pract; 2009 Dec;12(4):379-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal cancer in North--Eastern Nigeria: clinical trends.
  • BACKGROUND: Nasopharyngeal cancer is the malignancy of the posterior aspect of the nose called Nasopharynx.
  • AIM: To determine prevalence, clinical trends and histopathological types of Nasopharyngeal cancer in Maiduguri, North Eastern Nigeria.
  • PATIENTS AND METHOD: Fifteen year retrospective evaluation of patient's case notes and cancer registry records of 40 patients with histologically confirmed nasopharyngeal cancer between 1991-2005.
  • RESULTS: Nasopharyngeal cancers constituted 35.1% of all malignancies of ear, nose, throat during the study period.
  • The M:F was 2.1-1, the mean age was 39(+/- 16.5) years and a peak age group and its occurrence of 40-49 years.
  • The commonest histological type was squamous cell carcinoma(92.5%).
  • Patients who received chemotherapy in addition to radiotherapy and higher symptom free period.
  • CONCLUSION: Cancer is a difficult disease to diagnose at an stage.
  • A meticulous ear, nose and throat examination and thorough evaluation of nasal symptoms with associated cervical lymphadenopathy may lead to an early diagnosis of nasopharyngeal cancer's.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329676.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


16. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results.
  • OBJECTIVE: To evaluate the oncologic outcomes of patients with sinonasal cancer treated with endoscopic resection.
  • SETTING: Tertiary care academic cancer center.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • CONCLUSIONS: To the best of our knowledge, this is the largest US series to date of patients with malignant tumors of the sinonasal tract treated with endoscopic resection.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hannoud S, Rixe O, Bloch J, Le Pelletier F, Lebrun-Vignes B, Doarika A, Khayat D, Chosidow O: [Skin signs associated with epidermal growth factor inhibitors]. Ann Dermatol Venereol; 2006 Mar;133(3):239-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Manifestations cutanées des inhibiteurs du récepteur du facteur de croissance épidermique.
  • BACKGROUND: Inhibitors of epidermal growth factor receptors (EGFR) constitute a new alternative treatment for patients presenting certain advanced stage solid cancers (bowel, breast, ovary).
  • Adverse cutaneous effects of these drugs are now starting to be described.
  • OBSERVATIONS: Our study involved 2 men and 2 women with no previous history of acne included in a treatment protocol comprising EGFR inhibitors.
  • The primary cancers were breast, ovary, bowel and unidentified.
  • The severity of the rash resulted in discontinuation of treatment in 2 patients with complete disappearance of skin lesions in both cases.
  • Smears and cultures ofa nasal lesion and pustules revealed coagulase-positive Staphylococcus aureus in 2 patients.
  • DISCUSSION: EGFR inhibitors act by inhibiting mechanisms oftumour proliferation in certain cancers at advanced stages or refractory to other treatments.
  • This treatment must be instituted rapidly and patients must be informed about the cutaneous side-effects of EGFR inhibitors before the start of therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Drug Eruptions / etiology. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Adult. Female. Folliculitis / chemically induced. Humans. Male. Middle Aged. Neoplasms / drug therapy. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800173.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


18. Amusa YB, Adediran IA, Akinpelu VO, Famurewa OC, Olateju SO, Adegbehingbe BO, Komolafe EO, Faponle AF, Olasode BJ: Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital. West Afr J Med; 2005 Apr-Jun;24(2):139-42
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Burkitt's lymphoma is endemic in Nigeria; it forms about 39% of all childhood cancers.
  • In recent times more of these cases are being seen presenting first to the Ear Nose and Throat clinic.
  • OBJECTIVE: This study is designed to look at the pattern of presentation of head and Neck Burkitt's lymphoma at a Nigerian Tertiary hospital and to evaluate current treatment modality.
  • The proportion of the tumor affecting the Head and neck region were noted.
  • The most common sites that were affected are; the jaw (65.9%), nasal and paranasal sinuses (12.2).
  • Combination Chemotherapy comprising Cyclophosphamide, Oncovin, Methotrexate and Prednisolone (COMP) was the mainstay of management.
  • The treatment outcome was only favorable in 36.6%.
  • Frank drug resistance was found in (2.6%).
  • Some complications of treatment were noted.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Head and Neck Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] West Afr J Med. 2005 Jul-Sep;24(3):189. Adegbeingbe, OD [corrected to Adegbehingbe, BO]
  • (PMID = 16092315.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


19. McDaniel S, Goldman GD: Consequences of using escharotic agents as primary treatment for nonmelanoma skin cancer. Arch Dermatol; 2002 Dec;138(12):1593-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consequences of using escharotic agents as primary treatment for nonmelanoma skin cancer.
  • BACKGROUND: The use of escharotic or caustic pastes to treat skin cancer is based on the centuries-old observation that selected minerals and plant extracts may be used to destroy certain skin lesions.
  • Zinc chloride and Sanguinaria canadensis (bloodroot) are 2 agents that are used as part of the Mohs chemosurgery fixed-tissue technique.
  • Patients may now purchase "herbal supplements" for the primary self-treatment of skin cancer, and physicians will see patients who elect this therapy for their skin cancers.
  • Our search located numerous agents for purchase via the Internet that are advertised as highly successful treatments for skin cancer.
  • We report 4 cases from our practice in which escharotic agents were used by patients to treat basal cell carcinomas in lieu of the recommended conventional treatment.
  • One patient had a complete clinical response, but had a residual tumor on follow-up biopsy.
  • One patient presented with a nasal basal cell carcinoma that "healed" for several years following treatment elsewhere with an escharotic agent but recurred deeply and required an extensive resection.
  • CONCLUSIONS: Escharotic agents are available as herbal supplements and are being used by patients for the treatment of skin cancer.
  • Conventional medicine has an excellent track record in treating skin cancer.
  • Physicians should recommend against the use of escharotic agents for skin cancer, and the Food and Drug Administration should be given the authority to regulate their production and distribution.
  • [MeSH-major] Alkaloids / therapeutic use. Carcinoma, Basal Cell / drug therapy. Facial Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Biopsy, Needle. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Middle Aged. Mohs Surgery / methods. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12472348.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Curaderm
  •  go-up   go-down


20. Gladkova ND, Maslennikova AV, Balalaeva IV, Vysel'tseva IuV, Terent'eva AB, Il'in NV, Lazareva VA: [Potential of optical coherence tomography for diagnosing mucositis in cancer of the nasal cavity and throat in the course of radio- and chemoradiotherapy]. Vopr Onkol; 2006;52(4):443-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Potential of optical coherence tomography for diagnosing mucositis in cancer of the nasal cavity and throat in the course of radio- and chemoradiotherapy].
  • The monitoring data on mucosa of the nasal cavity and throat using optical coherence tomography imaging in 14 cases during radiochemotherapy are presented.
  • Typical alterations such as reduction in contrast distinctions between tissue layers to an extent that it blurs down completely at the peak of radiation-related response are discussed.
  • [MeSH-major] Mucositis / diagnosis. Mucositis / etiology. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Tomography, Optical Coherence
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Mouth Mucosa / drug effects. Mouth Mucosa / radiation effects. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024819.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


21. Dulguerov P, Allal AS: Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg; 2006 Apr;14(2):67-72
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal and paranasal sinus carcinoma: how can we continue to make progress?
  • PURPOSE OF REVIEW: New developments in the nasal and paranasal sinus cancers are reviewed.
  • RECENT FINDINGS: In addition to woodworking, several risk factors for nasal and paranasal sinus cancers have been identified, most notably smoking.
  • Progress in the differential diagnosis of small round cell nasal and paranasal sinus cancers allows the precise diagnosis of esthesioneuroblastoma.
  • Despite recent improvements, T staging for ethmoid and nasal cavity needs refinement.
  • An association of surgery and radiation therapy remains the best treatment modality.
  • Major developments include endoscopic resection of nasal and paranasal sinus cancers, high-precision radiotherapy techniques such as intensity-modulated radiotherapy, and proton-beam radiotherapy.
  • There is probably no role for chemotherapy in esthesioneuroblastoma.
  • Although chemotherapy is important for aggressive neoplasms, its generalized use for nasal and paranasal sinus cancers awaits the application/development of newer drugs.
  • These drugs might be applied locally since the majority of recurrences remain local.
  • SUMMARY: Progress in the treatment of nasal and paranasal sinus cancers could be achieved through better prevention and the developments of more selective treatments such as endoscopic resection, high-precision radiotherapy, and new chemotherapy drugs.
  • [MeSH-major] Carcinoma. Nasal Cavity / pathology. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552261.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


22. Garrott H, O'Day J: Optic neuropathy secondary to radiotherapy for nasal melanoma. Clin Exp Ophthalmol; 2004 Jun;32(3):330-3
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic neuropathy secondary to radiotherapy for nasal melanoma.
  • Optic neuropathy is a rare but important complication of radiotherapy used in the treatment of cancers of the head and neck, usually resulting in rapidly progressive blindness in one or both eyes.
  • The case is presented of a 77-year-old woman with bilateral optic neuropathy resulting in blindness, secondary to radiotherapy for a melanoma of the nasal cavity.
  • Despite treatment with oral anticoagulation and high dose intravenous methylprednisolone, there was progressive deterioration resulting in bilateral optic atrophy, with final visual acuities of perception of light in the right eye and no perception of light in the left eye.
  • This case demonstrates that oral anticoagulation was ineffective in the treatment of progressive radiation-induced optic neuropathy.
  • [MeSH-minor] Aged. Anticoagulants / therapeutic use. Drug Therapy, Combination. Female. Glucocorticoids / therapeutic use. Humans. Magnetic Resonance Imaging. Methylprednisolone / therapeutic use. Radiotherapy / adverse effects. Visual Fields. Warfarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Ophthalmol. 2004 Jun;32(3):233-5 [15180831.001]
  • (PMID = 15180849.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Glucocorticoids; 5Q7ZVV76EI / Warfarin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


23. Llorente JL, Pérez-Escuredo J, Alvarez-Marcos C, Suárez C, Hermsen M: Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review. Eur Arch Otorhinolaryngol; 2009 Jan;266(1):1-7
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review.
  • Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare epithelial cancer of the nasal cavities and paranasal sinuses.
  • Standard therapeutic modalities include surgery followed by radiotherapy in advanced stages, sometimes with chemotherapy treatment.
  • The molecular genetic mechanisms underlying the development and progression of this tumor is not understood.
  • This review aims to describe the clinico-pathological characteristics of this relatively unknown tumor and to summarize the knowledge on genetic and chromosomal analyses up to the present time.
  • [MeSH-major] Adenocarcinoma / etiology. Neoplasm Recurrence, Local / pathology. Occupational Exposure / adverse effects. Paranasal Sinus Neoplasms / etiology. Wood / adverse effects
  • [MeSH-minor] Dust. Female. Genetic Predisposition to Disease / epidemiology. Humans. Immunohistochemistry. Male. Molecular Biology. Neoplasm Staging. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2004 Mar;9(2):123-30 [15004509.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Surg Neurol. 1994 Aug;42(2):98-104 [8091301.001]
  • [Cites] Arch Otorhinolaryngol. 1988;245(1):1-15 [2839136.001]
  • [Cites] J Otolaryngol. 1993 Apr;22(2):86-90 [8515523.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Head Neck. 1998 May;20(3):224-31 [9570628.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4901-6 [15611505.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10 ):1080-3 [15452164.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):315-9 [15492756.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):740-2 [10699958.001]
  • [Cites] Acta Otolaryngol Suppl. 1998;535:1-16 [9725790.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1109-19 [12360473.001]
  • [Cites] Br Med J. 1968 Jun 8;2(5605):587-96 [5654629.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jul;135(1):135-9 [16815198.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):99-106 [15068833.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Cell. 2004 Sep 17;118(6):671-4 [15369667.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4817-25 [15256451.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1513-9 [15860506.001]
  • [Cites] Acta Otolaryngol. 1986 May-Jun;101(5-6):501-8 [3727983.001]
  • [Cites] Acta Otorrinolaringol Esp. 2008 May;59(5):235-8 [18501159.001]
  • [Cites] Acta Otorrinolaringol Esp. 2004 Jan;55(1):27-33 [15108619.001]
  • [Cites] Laryngoscope. 2008 Mar;118(3):437-43 [18176354.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2154-9 [18186150.001]
  • [Cites] Am J Surg Pathol. 1982 Dec;6(8):803-9 [7168462.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] Head Neck. 2006 Oct;28(10 ):909-15 [16906516.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Pathol. 2005 Oct;207(2):207-15 [16041693.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):199-204 [8685214.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):196-203 [12673679.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Acta Otolaryngol. 1984 Sep-Oct;98(3-4):321-34 [6496064.001]
  • [Cites] Cancer Lett. 1998 Apr 10;126(1):59-65 [9563649.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):482-8 [6733678.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Sep;114(9):996-9 [3408582.001]
  • (PMID = 18560862.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dust
  • [Number-of-references] 47
  •  go-up   go-down


24. da Lilly-Tariah OB, Somefun AO, Adeyemo WL: Current evidence on the burden of head and neck cancers in Nigeria. Head Neck Oncol; 2009;1:14
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current evidence on the burden of head and neck cancers in Nigeria.
  • BACKGROUND: Head and neck cancers (HNC) constitute 5-8% of total body cancers in Europe and America.
  • It is difficult to appreciate the problem of cancers in Nigeria because most studies available are hospital-based studies.
  • The aim of this study is to highlight current evidence on the burden of head and neck cancers in Nigeria based on literature review and to discuss potential health care actions to improve management.
  • METHODS: A literature search using Medline was conducted for publications on head and neck cancer in Nigeria.
  • The full-texts of these articles were thoroughly examined for the occurrence, distribution, identified risks factors, presentations, diagnostic method, treatment, prognosis and challenges associated with the management of HNC.
  • RESULTS: A total of twenty-seven relevant published articles on Head and neck cancers from 1968 to 2008 were reviewed.
  • Reports on the overall pattern of Head and neck cancers from different regions of the country cited nasopharynx as the commonest site for HNC, the sino-nasal is the second commonest while larynx, is the third commonly affected site.
  • Late presentation with advanced disease is common and treatment in most cases is palliative either with surgery or chemotherapy, and radiotherapy when available.
  • There are few reports on the outcome of HNC treatment in Nigeria.
  • CONCLUSION: The burden of managing HNC in Nigeria is enormous and the government should set up the National Cancer Institute with a view of educating the public on cancer prevention, detection and treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Niger Postgrad Med J. 2007 Mar;14(1):72-5 [17356597.001]
  • [Cites] East Afr Med J. 2006 May;83(5):288-91 [16866224.001]
  • [Cites] Acta Otolaryngol. 2007 Nov;127(11):1218-21 [17851930.001]
  • [Cites] Dent Clin North Am. 2008 Jan;52(1):1-17, vii [18154862.001]
  • [Cites] CA Cancer J Clin. 2008 Jan-Feb;58(1):32-53 [18096865.001]
  • [Cites] Nig Q J Hosp Med. 2007 Jul-Sep;17(3):120-5 [18318108.001]
  • [Cites] Afr J Med Med Sci. 2007 Dec;36(4):299-304 [18564644.001]
  • [Cites] J Natl Med Assoc. 2008 Jun;100(6):690-7 [18595571.001]
  • [Cites] J Oral Maxillofac Surg. 2008 Aug;66(8):1595-9 [18634945.001]
  • [Cites] Ann Trop Med Parasitol. 1947 Dec;41(3-4):321-8 [18902132.001]
  • [Cites] West Afr J Med. 1999 Jul-Sep;18(3):179-82 [10593153.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):945-51 [10888767.001]
  • [Cites] West Afr J Med. 2001 Apr-Jun;20(2):111-6 [11768008.001]
  • [Cites] Trop Doct. 2002 Oct;32(4):236-7 [12405310.001]
  • [Cites] Niger Postgrad Med J. 2003 Jun;10(2):99-102 [14567045.001]
  • [Cites] Niger Postgrad Med J. 2003 Jun;10(2):103-6 [14567046.001]
  • [Cites] J Laryngol Otol. 1968 Dec;82(12):1119-28 [4903356.001]
  • [Cites] Niger Med J. 1978 Mar-Apr;8(2):119-23 [206069.001]
  • [Cites] IARC Sci Publ. 1984;(63):501-11 [6536622.001]
  • [Cites] Semin Surg Oncol. 1989;5(5):305-9 [2814139.001]
  • [Cites] CA Cancer J Clin. 1990 Jan-Feb;40(1):9-26 [2104569.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1288-96 [2400977.001]
  • [Cites] West Afr J Med. 1990 Oct-Dec;9(4):304-10 [2083210.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] BMJ. 1994 Apr 9;308(6934):961-6 [8173406.001]
  • [Cites] CA Cancer J Clin. 1995 Jan-Feb;45(1):5-7 [7804898.001]
  • [Cites] Cent Afr J Med. 1999 Feb;45(2):40-2 [10444898.001]
  • [Cites] Trop Doct. 2005 Jan;35(1):2-4 [15712528.001]
  • [Cites] West Afr J Med. 2004 Oct-Dec;23(4):280-5 [15730084.001]
  • [Cites] West Afr J Med. 2004 Oct-Dec;23(4):305-13 [15730089.001]
  • [Cites] East Afr Med J. 2006 Apr;83(4):85-91 [16863003.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 May;36(5):403-8 [17391919.001]
  • (PMID = 19476614.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2694192
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


25. Majumder A, Devi HP, Singh TI: Unusual clinical presentation of nasopharyngeal carcinoma--report of 3 cases. J Indian Med Assoc; 2008 Jan;106(1):46, 48, 52
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among head and neck cancers, nasopharyngeal carcinoma has the poorest prognosis because of the primary site's proximity to the base of the skull and multiple vital structures.
  • The presenting symptoms are generally being nasal obstruction, epistaxis, painless cervical lymphadenopathy, etc.
  • They all were treated with combination chemotherapy and external beam radiation.
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Endoscopy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705270.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


26. Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M: Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med; 2008 Jan;33(1):14-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioguided surgical strategy in mucosal melanoma of the nasal cavity.
  • Sinonasal mucosal melanoma (MM), although very rare (<1% of the all MM), is second only to squamous cell carcinoma among cancers of the nasal region and still represents a challenging problem in head and neck cancer.
  • A 60-year-old woman had nasal MM stage I, which was treated with concomitant probe-guided tumor excision and an elective neck dissection after sentinel lymph node biopsy.
  • The radioactivity status of the tumor and lymph nodes were compared with the histopathologic specimen.
  • Surgical margins, sentinel lymph node, and lymphadenectomy were free of tumor.
  • The patient was seen in frequent and regular follow-up and was free of disease without any other treatment (radiotherapy, immunotherapy, or chemotherapy).
  • A multidisciplinary approach and further studies with a longer follow-up are needed to substantiate the accuracy and safety of this strategy in the treatment of an aggressive neoplasm like MM of the head and neck, which still has a very poor prognosis.
  • [MeSH-major] Melanoma / surgery. Nose Neoplasms / surgery
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Female. Gamma Cameras. Humans. Middle Aged. Radiosurgery. Sentinel Lymph Node Biopsy. Technetium Tc 99m Aggregated Albumin. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097249.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


27. Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF: Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol Cancer Ther; 2006 Sep;5(9):2234-40
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite advances in surgery, radiation, and chemotherapy, novel therapeutics are needed for head and neck cancer treatment.
  • The objective of this current study was to evaluate alexidine dihydrochloride as a novel compound lead for head and neck cancers.
  • Using a tetrazolium-based assay, the dose required to reduce cell viability by 50% (ED50) was found to be approximately 1.8 micromol/L in FaDu (human hypopharyngeal squamous cancer) and approximately 2.6 micromol/L in C666-1 (human undifferentiated nasopharyngeal cancer) cells.
  • In contrast, the ED50 values were much higher in untransformed cells, specifically at approximately 8.8 micromol/L in GM05757 (primary normal human fibroblast), approximately 8.9 micromol/L in HNEpC (primary normal human nasal epithelial), and approximately 19.6 micromol/L in NIH/3T3 (mouse embryonic fibroblast) cells.
  • Mitochondrial membrane potential (DeltaPsiM) depolarization was detectable after only 3 hours of treatment, and was followed by cytosolic Ca2+ increase along with loss of membrane integrity/cell death.
  • FaDu cell clonogenic survival was reduced to < 5% with 1 micromol/L alexidine dihydrochloride, and, correspondingly, this compound decreased the in vivo tumor-forming potential of FaDu cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Biguanides / pharmacology. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Caspase 2 / metabolism. Caspase 9 / metabolism. Cisplatin / administration & dosage. Enzyme Activation / drug effects. Female. Fluorouracil / administration & dosage. Humans. Membrane Potentials / drug effects. Mice. Mice, Inbred BALB C. Mice, SCID. Mitochondrial Membranes / drug effects. Mitochondrial Membranes / physiology. NIH 3T3 Cells. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985057.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biguanides; EC 3.4.22.- / Caspase 2; EC 3.4.22.- / Caspase 9; GVN71CAL3G / alexidine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Woo JK, Choi DS, Tran HT, Gilbert BE, Hong WK, Lee HY: Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev Res (Phila); 2009 Apr;2(4):361-9
Hazardous Substances Data Bank. ROTENONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deguelin has shown promising chemopreventive and therapeutic activities in diverse types of cancers.
  • However, the potential side effect of deguelin over a certain dose could be the substantial hurdle in the practical application of the drug.
  • One of the successful strategies for the use of deguelin in clinical trials could be lung-specific delivery of the drug.
  • The present study evaluates the efficacy of liposome-encapsulated deguelin with a dose of 0.4 mg/kg, which is 10 times less than the dose (4 mg/kg) for preventive and therapeutic activities validated in previous in vivo studies.
  • Liposomal deguelin revealed cytotoxic activity in vitro in premalignant and malignant human bronchial epithelial cells and non-small cell lung cancer cells through the same mechanistic pathway previously reported for deguelin (i.e., suppression of the heat shock protein 90 chaperone function and induction of apoptosis).
  • Delivery of liposomal deguelin at a dose of 0.4 mg/kg by intranasal instillation resulted in markedly increased drug partitioning to the lungs compared with that of 4 mg/kg deguelin or 0.4 mg/kg liposomal deguelin administered by oral gavage.
  • Lung-specific delivery of deguelin (0.4 mg/kg) via nasal or intratracheal instillation in a liposomal formulation also showed significant chemopreventive and therapeutic activities in 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone/benzo(a)pyrene-treated A/J mice and K-rasLAC57Bl6/129/sv F1 mice with no detectable toxicity.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3380-4 [9520374.001]
  • [Cites] Cell. 1997 May 2;89(3):457-67 [9150145.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1557-65 [9794233.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(3):177-86 [10453718.001]
  • [Cites] Chem Res Toxicol. 2004 Nov;17(11):1540-8 [15540952.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48846-54 [15358771.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6682-91 [15613472.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4151-9 [15930351.001]
  • [Cites] Int J Radiat Biol. 2005 Jan;81(1):63-76 [15962764.001]
  • [Cites] J Chemother. 2005 Jun;17(3):297-301 [16041863.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6065-74 [16115952.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1695-9 [16288123.001]
  • [Cites] Neoplasia. 2005 Dec;7(12):1053-7 [16354587.001]
  • [Cites] Mol Pharmacol. 2007 Jan;71(1):101-11 [17035597.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):949-61 [17565155.001]
  • [Cites] Pulm Pharmacol Ther. 2007;20(6):629-41 [17015027.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):5-14 [17764071.001]
  • [Cites] Curr Drug Deliv. 2007 Oct;4(4):297-305 [17979650.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3429-35 [9270009.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2876-80 [10914737.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3669-74 [11325837.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2228-36 [11489796.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3530-7 [12068000.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2446-54 [12460790.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):291-302 [12591985.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23630-8 [12714585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13791-6 [14614132.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1074-9 [14871987.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2319-26 [15073107.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6693-7 [1323115.001]
  • [Cites] Biochem Mol Biol Int. 1995 Jan;35(1):95-102 [7735144.001]
  • [Cites] Chem Res Toxicol. 1998 Jun;11(6):559-603 [9625726.001]
  • (PMID = 19336726.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100816-02; United States / NCI NIH HHS / CA / R01 CA109520-01; United States / NCI NIH HHS / CA / CA109520-01; United States / NCI NIH HHS / CA / R01 CA109520-05; United States / NCI NIH HHS / CA / R01 CA109520-04; United States / NCI NIH HHS / CA / CA100816-02; United States / NCI NIH HHS / CA / R01 CA100816; United States / NCI NIH HHS / CA / R01 CA100816-03; United States / NCI NIH HHS / CA / R01 CA109520-03; United States / NCI NIH HHS / CA / R01 CA100816-01A1; United States / NCI NIH HHS / CA / R01 CA100816-01; United States / NCI NIH HHS / CA / CA109520-03; United States / NCI NIH HHS / CA / CA109520-05; United States / NCI NIH HHS / CA / CA100816-01A1; United States / NCI NIH HHS / CA / CA100816-04; United States / NCI NIH HHS / CA / CA109520-02; United States / NCI NIH HHS / CA / R01 CA100816-04; United States / NCI NIH HHS / CA / R01 CA109520-02; United States / NCI NIH HHS / CA / CA109520-04; United States / NCI NIH HHS / CA / R01 CA109520; United States / NCI NIH HHS / CA / CA100816-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 03L9OT429T / Rotenone; K5Z93K66IE / deguelin
  • [Other-IDs] NLM/ NIHMS115847; NLM/ PMC2743316
  •  go-up   go-down






Advertisement